Didemnin B is a cyclic depsipeptide produced by marine tunicates that specifically binds the GTP-bound conformation of EEF1A, inhibiting its release from the ribosomal A site and preventing subsequent peptide elongation.Didemnin B thereby specifically inhibits eEF1A-1 release from the ribosomal A-site, preventing peptidyl-tRNA translocation and subsequent peptide elongation. It is a potential anticancer, antiviral, and immunosuppressive agent[1,2].
Didemnin B (80 nM,48h) prevent upregulation of GRP78 protein in HepG2 cells,in association with sustained inhibition of protein synthesis[3]. The structurally unrelated cyclic peptides didemnin B and ternatin-4 bind to the eEF1A(GTP)-aa-tRNA ternary complex and inhibit translation but have different effects on protein synthesis in vitro and in vivo. By binding to a common site on eEF1A, didemnin B and ternatin-4 trap eEF1A in an intermediate state of aa-tRNA selection, preventing eEF1A release and aa-tRNA accommodation on the ribosome[5]. Didemnin B can induce apoptosis in a wide range of transformed cell lines[6].
Acute intervention with the EEF1A inhibitor, didemnin B, improves hepatic lipotoxicity in obese mice with NAFLD through mechanisms not entirely dependent on decreased food intake, suggesting a potential therapeutic strategy for this ER stress-related disease[4].Didemnin B improves hepatic steatosis, glucose tolerance, and blood lipids in obesity, in association with moderate, possibly hormetic, upregulation of pathways involved in cell stress response and energy balance in the liver[7].
References:
[1]. Marco E, Martín-Santamaría S, et,al. Structural basis for the binding of didemnins to human elongation factor eEF1A and rationale for the potent antitumor activity of these marine natural products. J Med Chem. 2004 Aug 26;47(18):4439-52. doi: 10.1021/jm0306428. PMID: 15317456.
[2]. Lee J, Currano JN, et,al. Didemnins, tamandarins and related natural products. Nat Prod Rep. 2012 Mar;29(3):404-24. doi: 10.1039/c2np00065b. Epub 2012 Jan 23. PMID: 22270031.
[3]. Stoianov AM, Robson DL, et,al. Elongation Factor 1A-1 Is a Mediator of Hepatocyte Lipotoxicity Partly through Its Canonical Function in Protein Synthesis. PLoS One. 2015 Jun 23;10(6):e0131269. doi: 10.1371/journal.pone.0131269. PMID: 26102086; PMCID: PMC4478042.
[4]. Hetherington AM, Sawyez CG, et,al. Treatment with didemnin B, an elongation factor 1A inhibitor, improves hepatic lipotoxicity in obese mice. Physiol Rep. 2016 Sep;4(17):e12963. doi: 10.14814/phy2.12963. PMID: 27613825; PMCID: PMC5027364.
[5]. Juette MF, Carelli JD, et,al. Didemnin B and ternatin-4 differentially inhibit conformational changes in eEF1A required for aminoacyl-tRNA accommodation into mammalian ribosomes. Elife. 2022 Oct 20;11:e81608. doi: 10.7554/eLife.81608. PMID: 36264623; PMCID: PMC9584604.
[6]. Baker MA, Grubb DR, et,al. Didemnin B induces apoptosis in proliferating but not resting peripheral blood mononuclear cells. Apoptosis. 2002 Oct;7(5):407-12. doi: 10.1023/a:1020078907108. PMID: 12207173.
[7]. Wilson RB, Chen YJ, et,al.The marine compound and elongation factor 1A1 inhibitor, didemnin B, provides benefit in western diet-induced non-alcoholic fatty liver disease. Pharmacol Res. 2020 Nov;161:105208. doi: 10.1016/j.phrs.2020.105208. Epub 2020 Sep 22. PMID: 32977024.
Didemnin B 是一种由海洋被囊类动物产生的环状肽肽,可特异性结合 EEF1A 的 GTP 结合构象,抑制其从核糖体 A 位点释放并防止随后的肽延伸。Didemnin B 从而特异性抑制 eEF1A-1 从核糖体释放A 位点,防止肽基-tRNA 易位和随后的肽延伸。它是一种潜在的抗癌剂、抗病毒剂和免疫抑制剂[1,2]。
Didemnin B (80 nM,48h) 阻止 HepG2 细胞中 GRP78 蛋白的上调,并持续抑制蛋白质合成[3]。结构无关的环肽 didemnin B 和 ternatin-4 与 eEF1A(GTP)-aa-tRNA 三元复合物结合并抑制翻译,但在体外和体内对蛋白质合成有不同的影响。通过与 eEF1A 上的共同位点结合,didemnin B 和 ternatin-4 将 eEF1A 捕获在 aa-tRNA 选择的中间状态,从而阻止 eEF1A 释放和 aa-tRNA 在核糖体上的调节[5]。 Didemnin B 可在多种转化细胞系中诱导细胞凋亡[6]。
用 EEF1A 抑制剂 didemnin B 进行急性干预,可通过不完全依赖于食物摄入量减少的机制改善患有 NAFLD 的肥胖小鼠的肝脏脂毒性,表明这种 ER 应激相关疾病的潜在治疗策略[4]< /sup>.Didemnin B 改善肥胖患者的肝脂肪变性、葡萄糖耐量和血脂,与适度的、可能是激素性的、参与肝脏细胞应激反应和能量平衡的通路上调有关[7].
















